ストックスクリーナーアプリを入手
23.82
0.17%
-0.04
アフターアワーズ：
23.74
-0.08
-0.34%
Lb Pharmaceuticals Inc (LBRX) 最新ニュース
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week HighTime to Buy? - MarketBeat
LB Pharmaceuticals announces $100.0 million private placement - marketscreener.com
LB Pharmaceuticals Announces $100 Million Private Placement Financing - TipRanks
LB Pharmaceuticals Signs Multiple Material Agreements - TradingView
Lb Pharmaceuticals Announces $100.0 Million Private Placement - TradingView
LB Pharmaceuticals Announces $100.0 Million Private Placement - The Manila Times
LB Pharmaceuticals lines up $100M for new depression trial - stocktitan.net
Sector Update: Health Care - marketscreener.com
LB Pharmaceuticals Advances LB-102 Into Long-Term Phase 3 Safety Study for Schizophrenia - TipRanks
LB Pharmaceuticals initiates phase 2 trial for bipolar depression drug By Investing.com - Investing.com Australia
LB Pharmaceuticals initiates Phase 2 trial of LB-102 - Yahoo Finance
LB Pharmaceuticals (NASDAQ:LBRX) Shares Down 6.4%Time to Sell? - MarketBeat
LB Pharmaceuticals initiates phase 2 trial for bipolar depression drug - Investing.com
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in - GlobeNewswire
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program - Sahm
LB Pharmaceuticals Advances LB-102 Into Phase 3, Setting Up a Key Schizophrenia Catalyst for Investors - TipRanks
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighWhat's Next? - MarketBeat
LB Pharmaceuticals appoints Minako Pazdera as general counsel By Investing.com - Investing.com Nigeria
FDA clears Lexicon’s pilavapadin to advance to Phase 3 trials By Investing.com - Investing.com Nigeria
FDA clears Lexicon’s pilavapadin to advance to Phase 3 trials - Investing.com
LB Pharmaceuticals appoints Minako Pazdera as general counsel - Investing.com
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel - manilatimes.net
Viatris launches heart failure drug Inpefa in UAE, first outside US - Investing.com
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 5.5%What's Next? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Up 7.7%Time to Buy? - MarketBeat
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
LB Pharmaceuticals (NASDAQ:LBRX) Coverage Initiated at Roth Capital - Defense World
LB Pharmaceuticals (NASDAQ:LBRX) Stock Rating Upgraded by Roth Capital - MarketBeat
Roth/MKM initiates LB Pharmaceuticals stock with Buy rating on schizophrenia drug potential - Investing.com Australia
Roth/MKM initiates LB Pharmaceuticals stock with Buy rating on schizophrenia drug potential By Investing.com - Investing.com South Africa
PR News | On the Move: The Trevor Projects Names Wong CCOThu., Jan. 8, 2026 - O'Dwyer's PR
Poplar’s $50 million Series A to ‘transform treatment of atopic diseases’ - The Pharma Letter
LB Pharmaceuticals appoints two executives to leadership team By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Appoints Ellen Rose and Lindsay Beaupre as Senior Vice Presidents - citybiz
LB Pharmaceuticals appoints two executives to leadership team - Investing.com India
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture - The Manila Times
0.23%
1.25%
大文字化:
|
ボリューム (24 時間):